Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrabronchial liposomal amphotericin B for simple pulmonary aspergilloma
2025-523501-15-00Phase 2Authorised
- Sponsor
- Pauls Stradins Clinical University Hospital
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amphotericin b in pulmonary aspergilloma, sponsored by Pauls Stradins Clinical University Hospital. Primary endpoint: Relative change in lesion size. Planned start Mar 2026; status: authorised.
02
Drugs
amphotericin b
03
Conditions
pulmonary aspergilloma
Beyond the preview
Go deeper on 2025-523501-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523501-15-00.